Teclistamab/Talquetamab Hits Record Low Hazard Ratio in Multiple Myeloma
Topline results from the phase 3 MonumenTAL-6 trial (NCT06208150) showed that teclistamab-cqyv (Tecvayli) plus talquetamab-tgvs (Talvey) reduced the…
Browsing Category